See at a glance what Vernalis has in development
See the status of all programmes, both partnered and un-partnered.
Explore NCE Pipeline
We have two programmes in CNS both focussed on pain management
Central Nervous System
We have six programmes in Oncology
Four partnered and two available for out-licensing
We have a single programme focussed on inflammation which is partnered
Vernalis plc announced today that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for CCP-08.
More information on Vernalis and its pipeline ...
Company fact sheet
Explore the pipeline ...
T: 0118 938 0000 F: 0118 938 0001Contact informationMaps and directionsContact form
To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and firstname.lastname@example.org or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch